(RTTNews) - Medical technology company Zynex, Inc. (ZYXI) announced Tuesday that it has received clearance from the U.S. Food and Drug Administration for the next generation M-Wave Neuromuscular Electrical Stimulation or NMES device.
NMES treatments have several uses, including aiding recovery from surgery, managing chronic conditions, and even enhancing exercise performance in healthy individuals.
The M-Wave replaces its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998.
The M-Wave is designed to improve the way patients manage their neuromuscular conditions. With advanced features and a user-friendly design, the M-Wave allows patients to be treated quickly in a clinical or home setting.
The compact and lightweight design of the M-Wave ensures portability and easy integration into patients' recovery routines.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
